Bart Barlogie, MD
- PROFESSOR | Medicine, Hematology and Medical Oncology
Bart Barlogie, MD, joined the Icahn School of Medicine as Director of Myeloma Research in 2015.
He had previously headed the Myeloma Institute at the University of Arkansas for Medical Sciences, which he founded in 1989. Under his leadership, a world-renowned program for multiple myeloma research and therapy was established, focusing on "Growth Control in Multiple Myeloma" with the therapeutic goal to achieve cure through the use of myeloablative cytotoxic and immunological treatment strategies.
Dr. Barlogie earned his post-graduate degrees at Heidelberg University and the Max Planck Institute for Medical Research. Following residency at the Universities of Munich and Muenster, he joined MD Anderson Hospital and Tumor Research Institute as a Fellow under Dr. Emil J Freireich. Dr. Barlogie's initial laboratory investigation was dedicated to studying tumor cell cycle kinetics and its implications for designing combination chemotherapy. Dr. Barlogie was one of the first to demonstrate that DNA aneuploidy was a convenient marker for malignancies in most human tumor specimens. Dr. Barlogie's clinical studies have focused on biological and therapeutic research, including chemotherapy, immunotherapy and hematopoietic stem cell transplantation.
His notable contributions include:
· Introducing the first effective salvage regimen for alkylating agent refractory myeloma;
· Introducing autologous transplants for myeloma;
· Discovering the activity of thalidomide as the first novel agent in myeloma therapy;
· Developing the first curative therapy for myeloma through “Total Therapy” protocols that employed all active agents up-front;
· Introducing genomic profiling into myeloma research for identification of risk-stratified disease subgroups;
· Introducing novel imaging techniques (MRI and PET-CT) for myeloma staging and response assessment;
· Developing reproducible prognostic models for myeloma;
· Identifying myelodysplasia as a consequence of myeloma therapy.
During his tenure in Arkansas, Dr. Barlogie was awarded 20 years of continuous funding from the National Cancer Institute through a P01 program project grant—"Growth Control in Multiple Myeloma"—the first P01 awarded for multiple myeloma.
Heis now focusing his attention on the 15% of patients presenting with genomically defined high-risk MM, by applying metronomically scheduled chemotherapy and targeting mutations.
Dr. Barlogie has published extensively, including more than 580 peer reviewed journal articles including four in the New England Journal of Medicine and 75 book chapters.
- Hematologic Malignancies
- Multiple Myeloma
Fellowship, Internal Medicine, MD Anderson Cancer Center (Univ of Texas)
1991 Fellow, American College of Physicians
2002 American Society of Neuroradiology Award for Excellence (Scientific Exhibit)
2014 Israel Cancer Research Fund – Special Guest at the Man of Distinguished Gala
1994 The Best Doctors in America
2014 Distinguished Professor of Medicine and Pathology – UAMS
2013 “Medal of the Faculty” from the University of Heidelberg in honor of life’s work on stem cell transplantation and multiple myeloma
2006 Castle Connolly Medical Ltd., National Physician Award of the Year
2003 The Francesca M. Thompson Outstanding Service Award International Myeloma Foundation
1998 The Best Doctors in America
1997 Distinguished Faculty Award – UAMS College of Medicine
2009 Castle Connolly America’s Top Doctors
1998 Distinguished Alumnus Award – UT M.D. Anderson Cancer Center
2015 Celgene Distinguished Endowed Chair in Molecular Therapeutics – Creation of Bart Barlogie Center for Molecular Diagnostics
2007 America’s Top Doctors for Cancer
2005-2006 Castle Connolly America’s Top Doctors for Cancer
2004 The Robert A. Kyle Lifetime Achievement Award
1995 Distinguished Faculty Scholar Award – UAMS College of Medicine
1976 American Cancer Society Fellowship Award
2002 Celgene Career Achievement Award in Hematolgy Research
1999 Jan Waldenström Award for Myeloma Research